trending Market Intelligence /marketintelligence/en/news-insights/trending/been-nfk2dhadzamn7vrla2 content esgSubNav
In This List

Halozyme Therapeutics director to step down

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Halozyme Therapeutics director to step down

Randal Kirk informed Halozyme Therapeutics Inc. of his unavailability to serve as a director due to his growing commitments outside of the company.

Due to this development, Kirk will not be nominated for re-election to the board at the upcoming stockholders' annual meeting.

San Diego, Calif.-based Halozyme Therapeutics is a biotechnology company which researches, develops, and commercializes human enzymes and other drug candidates in the U.S., Switzerland, and internationally.